Managing Anemia and Metabolic Bone Disease in Dialysis Patients
Authors:
- 14 June 2016
- book chapter
- Published by Springer Nature
- p. 93-102
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- FGF23: A Mature Renal and Cardiovascular Risk Factor?Blood Purification, 2013
- Vitamin D Treatment and Mortality in Chronic Kidney Disease: A Systematic Review and Meta-AnalysisAmerican Journal of Nephrology, 2013
- Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving DialysisNew England Journal of Medicine, 2013
- Peginesatide in Patients with Anemia Undergoing HemodialysisNew England Journal of Medicine, 2013
- Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing DialysisNew England Journal of Medicine, 2012
- Update on fibroblast growth factor 23 in chronic kidney diseaseKidney International, 2012
- Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney diseaseCurrent Opinion in Nephrology and Hypertension, 2012
- Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney DiseaseAnnals of Internal Medicine, 2010
- Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturationKidney International, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006